Johnson & Johnson (JNJ)

167.460
+0.280(+0.17%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    167.400 - 167.460
  • Type:Equity
  • Market:Austria
  • ISIN:US4781601046

JNJ Overview

Prev. Close
124.66
Day's Range
167.4-167.46
Revenue
-
Open
167.4
52 wk Range
133.22-174.38
EPS
-
Volume
0
Market Cap
443.61B
Dividend (Yield)
4.52
(2.51%)
Average Volume (3m)
48
P/E Ratio
-
Beta
-
1-Year Change
21.67%
Shares Outstanding
2,631,401,804
Next Earnings Date
-
What is your sentiment on J&J?
or
Market is currently closed. Voting is open during market hours.

Johnson & Johnson News

Johnson & Johnson Analysis

Johnson & Johnson Company Profile

Johnson & Johnson Company Profile

Employees
141700

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Read More

Technical Summary

Type
Daily
Weekly
Monthly
Moving AveragesNeutralBuyStrong Buy
Technical IndicatorsSellStrong BuyStrong Buy
SummaryNeutralStrong BuyStrong Buy
  • FDA approved finally. Few minutes ago!!!!
    0
    • What?
      0
  • Invested in J&J a couples years back and have closely followed the pharmaceutical industry. Found a company by the name of SpectrumX which has an IPO set for November. SpectrumX are leaders in patented shielded HOCL formulations that have numerous applications in medical/pharma fields. They have also undergone 2 clinical trails for Covid-19 treatment (apparently not factored into the company valuation.) To me this company seems to be on track for high growth after the IPO, however I may be getting lost in the hype. Would love to hear people's thoughts on the stock as I am keen to invest early.
    0
    • To entry in Spectrum or not? What do you think?
      0
    • Checking it out looks like a good punt
      0
  • Good job JNJ. move forward bullish
    0
    • Stock split???
      0
      • Where we go next?
        0
        • AMC! But ultimately it’s your decision.
          0
      • Good buy. 0at this price
        0
        • JNJ is going to Make a strong come back tonight!
          1
          • Immediate inquiry must be done
            4